[go: up one dir, main page]

MA33076B1 - Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer - Google Patents

Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer

Info

Publication number
MA33076B1
MA33076B1 MA33027A MA33027A MA33076B1 MA 33076 B1 MA33076 B1 MA 33076B1 MA 33027 A MA33027 A MA 33027A MA 33027 A MA33027 A MA 33027A MA 33076 B1 MA33076 B1 MA 33076B1
Authority
MA
Morocco
Prior art keywords
treatment
cancer
secretase inhibitor
gamma secretase
patient
Prior art date
Application number
MA33027A
Other languages
Arabic (ar)
English (en)
Inventor
John Frederick Boylan
Leopoldo Ladores Luistro Iii
Kathryn E Packman
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40365425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33076(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33076B1 publication Critical patent/MA33076B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION PORTE SUR UN PROCÉDÉ DE TRAITEMENT D'UN PATIENT AYANT UN CANCER, COMPRENANT L'ADMINISTRATION AU PATIENT D'UNE QUANTITÉ THÉRAPEUTIQUEMENT EFFICACE DE COMPOSÉ (1), OU D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, AYANT LA FORMULE : LA PRÉSENTE INVENTION PORTE ÉGALEMENT SUR UN COFFRET CONTENANT LE COMPOSÉ CI-DESSUS, AINSI QUE SUR L'UTILISATION DU COMPOSÉ (1) POUR LA FABRICATION DE MÉDICAMENTS POUR LE TRAITEMENT DU CANCER SELON LES DOSAGES ET LES PROGRAMMES SPÉCIFIQUEMENT DÉCRITS ICI.
MA33027A 2008-01-11 2009-01-05 Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer MA33076B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2044708P 2008-01-11 2008-01-11
PCT/EP2009/050047 WO2009087130A1 (fr) 2008-01-11 2009-01-05 Utilisation d'un inhibiteur de la gamma-sécrétase pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA33076B1 true MA33076B1 (fr) 2012-03-01

Family

ID=40365425

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33027A MA33076B1 (fr) 2008-01-11 2009-01-05 Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer

Country Status (17)

Country Link
US (1) US20090181944A1 (fr)
EP (1) EP2244713A1 (fr)
JP (3) JP5612482B2 (fr)
KR (2) KR20140007979A (fr)
CN (1) CN101909633B (fr)
AR (1) AR072442A1 (fr)
AU (1) AU2009203776A1 (fr)
BR (1) BRPI0906831A2 (fr)
CA (1) CA2710913A1 (fr)
CL (1) CL2009000040A1 (fr)
CR (1) CR11510A (fr)
IL (1) IL206361A0 (fr)
MA (1) MA33076B1 (fr)
RU (1) RU2010133489A (fr)
TW (1) TW200936139A (fr)
WO (1) WO2009087130A1 (fr)
ZA (1) ZA201004859B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2669693C (fr) 2006-11-15 2018-06-12 Massachusetts Eye & Ear Infirmary Generation de cellules de l'oreille interne
CA2743436C (fr) 2008-11-24 2017-10-31 Massachusetts Eye & Ear Infirmary Voies pour generer des cellules pileuses
US8309299B2 (en) * 2010-05-19 2012-11-13 Hoffmann-La Roche Inc. Combination therapy and method for assessing resistance to treatment
KR101330184B1 (ko) 2010-10-15 2013-11-15 성균관대학교산학협력단 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물
WO2012050370A2 (fr) * 2010-10-15 2012-04-19 성균관대학교산학협력단 Composition pour prévenir ou traiter la polyarthrite rhumatoïde contenant un inhibiteur de sécrétase gamma en tant que composant actif
US20120114638A1 (en) * 2010-11-08 2012-05-10 John Boylan Combination therapy
US20120225860A1 (en) * 2011-03-02 2012-09-06 John Frederick Boylan Method for administration of a gamma secretase inhibitor
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
JO3148B1 (ar) 2011-07-27 2017-09-20 Lilly Co Eli مركب مثبط لإشارات مسار notch
CA2884309A1 (fr) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methodes et compositions pour la regeneration des cellules de cheveux et/ou des cellules de soutien a partir de cellules cochleaires differenciees ou de cellules utriculaires differenciees par modulation de l'activite de notch et de c-myc
HK1211875A1 (en) 2012-09-07 2016-06-03 Massachusetts Eye & Ear Infirmary Treating hearing loss
US9249157B2 (en) 2012-09-21 2016-02-02 Bristol-Myers Squibb Company Tricyclic heterocycle compounds
CN104854094A (zh) 2012-09-21 2015-08-19 百时美施贵宝公司 氟烷基二苯并二氮杂*酮化合物
US9242940B2 (en) 2012-09-21 2016-01-26 Bristol-Myers Squibb Company N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds
US9273075B2 (en) 2012-09-21 2016-03-01 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
CN105308030A (zh) 2012-09-21 2016-02-03 百时美施贵宝公司 烷基、氟烷基-1,4-苯并二氮杂*酮化合物
CN104797569A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 取代的1,5-苯并二氮杂*酮化合物
CN104822677A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 氟烷基-1,4-苯并二氮杂*酮化合物
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
WO2014047397A1 (fr) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Composés de fluoralkyl- et de fluorocycloalkyl-1,4-benzodiazépinone utilisables en tant qu'inhibiteurs du récepteur notch
JP2016515625A (ja) * 2013-04-04 2016-05-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 増殖性疾患を治療するための併用療法
WO2015095116A1 (fr) * 2013-12-17 2015-06-25 Rush University Medical Center Compositions et méthodes pour le traitement de la néphropathie diabétique
US20170314027A1 (en) 2014-08-06 2017-11-02 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
WO2016069906A1 (fr) 2014-10-29 2016-05-06 Massachusetts Eye And Ear Infirmary Administration efficace de molécules thérapeutiques en direction de cellules de l'oreille interne
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
KR20180117628A (ko) 2016-01-29 2018-10-29 매사추세츠 아이 앤드 이어 인퍼머리 내이 지지 세포의 확장 및 분화 및 그의 사용 방법
WO2017180385A1 (fr) 2016-04-12 2017-10-19 Eli Lilly And Company Traitement d'association à base d'inhibiteurs de notch et de pi3k/mtor pour une utilisation dans le traitement du cancer
KR102362222B1 (ko) 2016-05-16 2022-02-11 더 제너럴 하스피탈 코포레이션 폐 상피 공학에서 인간 기도 줄기 세포
JP7194022B2 (ja) 2016-05-20 2022-12-21 イーライ リリー アンド カンパニー Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法
AU2017376109A1 (en) 2016-12-16 2019-07-11 Pipeline Therapeutics, Inc. Methods of treating cochlear synaptopathy
MA50564A (fr) 2017-11-06 2020-09-16 Hutchinson Fred Cancer Res Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase
KR102094442B1 (ko) 2018-06-28 2020-03-27 성균관대학교산학협력단 알쯔하이머성 치매의 예방 또는 치료용 물질 및 이를 포함하는 조성물
WO2022067185A1 (fr) * 2020-09-27 2022-03-31 Veru Inc. Méthodes de traitement du cancer de la prostate à effets secondaires minimes
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (fr) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6012A (en) * 1849-01-09 Lithographing co
KR100838852B1 (ko) * 2003-09-09 2008-06-16 에프. 호프만-라 로슈 아게 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체
US7211573B2 (en) * 2004-12-08 2007-05-01 Hoffmann-La Roche Inc. Malonamide derivatives
JP2008530232A (ja) * 2005-02-15 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 化学療法剤、ｉｌ−２および場合により抗ｃｄ２０抗体の組み合わせを使用してリンパ腫を処置する方法
EP1888051A2 (fr) * 2005-05-17 2008-02-20 MERCK SHARP & DOHME LTD. Cyclohexyl sulfone a substitution sulfonamido pour le traitement du cancer
US20080058316A1 (en) * 2006-02-27 2008-03-06 The Johns Hopkins University Cancer treatment with gama-secretase inhibitors

Also Published As

Publication number Publication date
JP2014221772A (ja) 2014-11-27
US20090181944A1 (en) 2009-07-16
CA2710913A1 (fr) 2009-07-16
WO2009087130A1 (fr) 2009-07-16
JP2013241443A (ja) 2013-12-05
CR11510A (es) 2010-09-13
EP2244713A1 (fr) 2010-11-03
RU2010133489A (ru) 2012-02-20
TW200936139A (en) 2009-09-01
JP5612482B2 (ja) 2014-10-22
KR20100101624A (ko) 2010-09-17
CN101909633B (zh) 2012-05-30
JP2011509273A (ja) 2011-03-24
CL2009000040A1 (es) 2010-02-12
KR20140007979A (ko) 2014-01-20
IL206361A0 (en) 2010-12-30
AU2009203776A1 (en) 2009-07-16
ZA201004859B (en) 2011-03-30
AR072442A1 (es) 2010-09-01
BRPI0906831A2 (pt) 2019-09-24
CN101909633A (zh) 2010-12-08

Similar Documents

Publication Publication Date Title
MA33076B1 (fr) Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
EA200800538A1 (ru) Терапевтические соединения
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
PH12016502355A1 (en) Pharmaceutical composition
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA201270570A1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
WO2009039397A3 (fr) Amides substitués, procédé pour les préparer et procédé pour les utiliser
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
EA200801997A1 (ru) Новые соединения
WO2009026176A3 (fr) Composés de flavononol anti-infectieux et leurs procédés d'utilisation
TW200806299A (en) Treatment of pain
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
ATE533489T1 (de) Behandlung von multiplem myelom
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
EP4327886A3 (fr) Composés de pyrimido-pyridazinone et leurs procédés d'utilisation
EA201170344A1 (ru) Азаиндольные ингибиторы iap
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
JO2999B1 (ar) مركب ثلاثي حلقي و استخدامه الدوائي